{"product_id":"twst-ansoff-analysis","title":"(TWST) Twist Bioscience Corporation ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Twist Bioscience Corporation Ansoff Matrix Analysis shows how the company can grow via market penetration, market development, product development, and diversification, and is used for strategic planning, investment screening, or presentations; the page includes a real preview\/sample of the analysis so you can evaluate style and substance before buying—purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustom synthetic genes in pharma R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience can deepen market penetration by selling more custom synthetic genes into its current biotech and pharma R\u0026amp;D accounts, lifting share of wallet without chasing new logos. Its silicon-based DNA platform supports repeat orders with fast turnaround and scale, which suits discovery teams that buy the same assays and constructs again and again.\u003c\/p\u003e\n\u003cp\u003eIn fiscal 2025, Twist reported revenue above $300 million, showing a larger installed base to upsell inside. The play is simple: more gene-order volume from the same customer set, backed by lower cost per sequence as throughput rises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntibody libraries with Boehringer Ingelheim\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Boehringer Ingelheim alliance gives Twist a direct route to increase antibody library use in therapeutic discovery, so this is a clear market penetration move. It deepens spend inside an existing biopharma tie-up and reinforces Twist’s role in antibody-enabled drug discovery. In FY2025 and FY2026, that matters because Twist is pushing more of its revenue mix toward higher-value pharma work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSample prep tools in sequencing workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation can deepen market penetration by putting more sample prep tools into the sequencing and research workflows of labs already buying its DNA synthesis and sequencing products. That matters because these kits sit upstream of read generation, so they can lift attach rates and repeat use without needing a new customer base. With NGS spending still expanding across clinical and research labs, even small share gains in existing accounts can add meaningful recurring revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-sell across the product catalog\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience Corporation can lift market penetration by cross-selling across a catalog that includes synthetic genes, sample prep tools, antibody libraries, and DNA data storage applications. In fiscal 2025, revenue reached about $374 million, showing room to grow account value inside the same life science base. The move matters because one customer can buy more than one product line instead of sourcing from separate vendors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eCross-sell raises wallet share.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eOne account, many product lines.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBest fit: current life science buyers.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSilicon-chip DNA platform scale advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s silicon-chip DNA platform is a direct market-penetration edge because it scales high-throughput synthesis for today’s demand. In fiscal 2025, Twist Bioscience Corporation reported $293.7 million in revenue, up 23% year over year, showing that volume growth is already converting into sales. Lower unit costs and faster output help Twist Bioscience Corporation defend share against smaller synthetic DNA rivals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-throughput silicon-chip synthesis\u003c\/li\u003e\n\u003cli\u003eFY2025 revenue: $293.7 million\u003c\/li\u003e\n\u003cli\u003e23% year-over-year growth\u003c\/li\u003e\n\u003cli\u003eScale supports share defense\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist Bioscience Deepens Share in Biotech and Pharma Accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s market penetration is strongest in existing biotech and pharma accounts, where repeat DNA synthesis orders and cross-sells can raise wallet share. FY2025 revenue was $293.7 million, up 23% year over year, showing deeper use inside its current customer base. The Boehringer Ingelheim alliance and sample prep attach rates can push more spend through the same labs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$293.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY growth\u003c\/td\u003e\n\u003ctd\u003e23%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Twist Bioscience Corporation’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Twist Bioscience Ansoff matrix to simplify growth planning and reduce strategic guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary, reputable sources to validate Twist Bioscience growth assumptions across product and market paths for fast, defensible Ansoff analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAustralia clinical genetics via Victorian Clinical Genetic Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s work with Victorian Clinical Genetic Services signals market development into Australia’s clinical genetics space. The same sequencing tools are now sold to a new geography and customer set, which fits Ansoff’s market development logic. Australia has about 27 million people, so this gives Twist a larger addressable base without changing its core platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean research and diagnostics via Vivlion and Centogene\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivlion GmbH and Centogene N.V. give Twist Bioscience Corporation direct access to European biotech and diagnostics channels, so it can sell the same DNA synthesis and sequencing tools into new geographies and customer groups. This is market development, not product change: Twist expands from its core U.S.-led base into Europe’s research and rare-disease testing networks. With one platform serving two routes to growth, the move can raise revenue without adding major product risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJapan pharma R\u0026amp;D via Kyowa Kirin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKyowa Kirin Pharmaceutical Research opens Twist Bioscience Corporation to Japanese pharma R\u0026amp;D, so this is market development using existing synthetic DNA and antibody tools. Twist reported $92.8 million in Q2 FY2025 revenue, up 18% year over year, which shows the core platform is still scaling. A new regional customer base like Japan can lift sales without changing the product set, which is the textbook Ansoff market development move.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew therapeutic antibody discovery customers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist’s antibody libraries are moving beyond one internal customer, so the same platform can reach more biopharma partners chasing therapeutic antibody discovery. The market is broad: more than 1,000 antibody-based drugs are in clinical development worldwide, which supports repeated demand for discovery tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame product, wider buyer base.\u003c\/li\u003e\n\u003cli\u003eMore partners, not new platform.\u003c\/li\u003e\n\u003cli\u003eTherapeutic discovery demand stays high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDNA data storage research buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience Corporation can push its DNA platform beyond gene synthesis into DNA data storage research, targeting labs, cloud-tech teams, and government buyers. Global data creation is forecast to reach 181 zettabytes in 2025, so even tiny DNA-storage pilots can attract new R\u0026amp;D spend outside Twist Bioscience Corporation’s core market. \u003c\/p\u003e\n\u003cp\u003eDNA storage still uses the same core chemistry, but the buyer changes: research groups want higher density, longer retention, and lower error rates. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew buyers: tech R\u0026amp;D and public labs\u003c\/li\u003e\n\u003cli\u003eCore asset: Twist Bioscience Corporation DNA platform\u003c\/li\u003e\n\u003cli\u003eUse case: data archiving research\u003c\/li\u003e\n\u003cli\u003eMarket driver: 181 zettabytes in 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist Bioscience Expands Into New Markets Without Changing Its Core Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s market development is clear: it is selling the same DNA synthesis and sequencing platform into new geographies and buyer groups, including Australia, Europe, Japan, and data-storage R\u0026amp;D. That keeps product risk low while widening addressable demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore revenue\u003c\/td\u003e\n\u003ctd\u003e$92.8M Q2 FY2025, +18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew markets\u003c\/td\u003e\n\u003ctd\u003eAustralia, Europe, Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWith global data creation forecast at 181 zettabytes in 2025, even small DNA-storage pilots can add new buyers without changing the core platform.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTwist Bioscience Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Ansoff Matrix report you'll get, and it outlines growth options for Twist Bioscience across market penetration, product development, market development, and diversification. Once purchased, you’ll receive the complete, editable version with strategic recommendations and implementation steps. Buy now to unlock the full, detailed Ansoff Matrix analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanded custom synthetic gene offerings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation can grow its synthetic gene line by adding new gene formats, tighter specs, and more service choices for the same research and biopharma customers. It already serves more than 3,000 customers, so product development can deepen wallet share without changing the market. That fits Twist’s core model: use its silicon-based DNA platform to sell more custom gene options to existing users.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized sample preparation tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience already sells sample prep tools, so upgrading them is a clear product-development play. In fiscal 2024, revenue rose to about $313 million, showing demand in its sequencing workflow base. Better kits can raise attach rates and keep Twist inside the same customer group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader antibody library portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s antibody libraries already anchor its pharma R\u0026amp;D sales, and the company reported about $374 million in FY2025 revenue. Adding new library content and discovery formats can widen that offer without leaving the same biopharma base. That matters because higher-value tools can lift wallet share from current customers and support repeat R\u0026amp;D use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTherapeutic antibody discovery applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience Corporation can turn its Boehringer Ingelheim alliance into a product-development offer for therapeutic antibody discovery. That fits an existing market relationship and builds on a FY2025 revenue base of about $313 million, showing the platform already has commercial traction. Structured library-to-hit discovery packages could deepen use of Twist’s antibody libraries in drug programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses an existing pharma alliance\u003c\/li\u003e\n\u003cli\u003eExtends antibody libraries into services\u003c\/li\u003e\n\u003cli\u003eTargets therapeutic discovery demand\u003c\/li\u003e\n\u003cli\u003eBuilds on FY2025 revenue scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDNA digital data storage applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience Corporation can extend DNA digital data storage into the same synthetic biology and advanced R\u0026amp;D base it already serves, turning a research tool into a new product line. With global data creation projected to hit 181 zettabytes in 2025, even small gains in DNA write\/read speed and cost could matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame buyers, new use case\u003c\/li\u003e\n\u003cli\u003eHigher-value product functionality\u003c\/li\u003e\n\u003cli\u003eFits existing R\u0026amp;D workflows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis is product development, not market expansion, because it deepens use inside the current scientific customer base. If Twist lowers synthesis and retrieval error rates, DNA storage can move from lab demos to repeatable research workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist Bioscience Expands Wallet Share With Higher-Value Product Upgrades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s product development strategy adds new features to existing gene synthesis, antibody, and workflow tools for the same research and biopharma buyers. FY2025 revenue was about $374 million, and its more than 3,000 customers give Twist room to sell higher-value versions without changing markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 base\u003c\/th\u003e\n\u003cth\u003eProduct development move\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e$374M revenue\u003c\/td\u003e\n\u003ctd\u003eNew formats, specs, kits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u0026gt;3,000 customers\u003c\/td\u003e\n\u003ctd\u003eDeeper wallet share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic antibody discovery into drug development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist’s antibody libraries can push it from DNA synthesis into therapeutic discovery, a clear diversification move that adds a new market and a more advanced use of its platform. Its libraries are built to screen vast sequence space, with antibody discovery systems often reaching 10^10 to 10^11 variants, which supports lead-finding for drug developers. For Twist Bioscience Corporation, that broadens the story from tools provider to drug-discovery partner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical genetics collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s collaboration with Victorian Clinical Genetic Services shifts its sequencing platform from standard research supply into clinical genetics, a higher-bar market with stricter validation and patient-use requirements. That is a clear diversification move in the Ansoff Matrix: same core technology, new application context. It also broadens Twist’s reach beyond RUO into clinical workflows, where one successful diagnostic program can support recurring test volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean diagnostics and biotech services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist’s partnerships with Centogene and Vivlion open access to 2 European diagnostics and biotech service channels, moving it beyond synthesized DNA products. \u003c\/p\u003e\n\u003cp\u003eThis is a diversification play in the Ansoff Matrix: a new market, but still tied to Twist’s platform-based sequencing and library prep applications. \u003c\/p\u003e\n\u003cp\u003eThat mix can widen revenue beyond product sales and strengthen recurring service demand. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJapan pharmaceutical research alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKyowa Kirin gives Twist Bioscience Corporation a route into Japan’s pharma R\u0026amp;D market, which is the world’s third-largest by spending. The core DNA synthesis platform stays the same, but the customer set, buying rules, and geography are different, so this is true diversification across end users and regions. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJapan adds a separate pharma demand pool\u003c\/li\u003e\n\u003cli\u003eSame platform, new commercial use case\u003c\/li\u003e\n\u003cli\u003eBroadens revenue beyond U.S. biotech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDNA data storage as a technology market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDNA data storage pushes Twist Bioscience Corporation into a tech market beyond gene synthesis and antibody tools. That makes it true diversification: the buyer is a data or cloud player, not only a life-science lab, so demand is less tied to research spending cycles.\u003c\/p\u003e\n\u003cp\u003eThe market is still early and pre-scale, so it is more option value than near-term revenue. Twist’s latest reported FY2025 revenue was still driven by core synthetic biology, while DNA storage mainly expands the long-term addressable market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew end market: digital data storage\u003c\/li\u003e\n\u003cli\u003eLess dependence on gene synthesis demand\u003c\/li\u003e\n\u003cli\u003eEarly-stage, high-upside diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist Bioscience Expands Beyond Gene Synthesis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s diversification goes beyond gene synthesis into antibody discovery, clinical genetics, and DNA data storage. Its antibody libraries can screen about 10^10 to 10^11 variants, while DNA storage opens a non-life-science market. These moves add new buyers, new use cases, and more optionality than core product sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntibody libraries\u003c\/td\u003e\n\u003ctd\u003eDrug discovery\u003c\/td\u003e\n\u003ctd\u003e10^10-10^11 variants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical genetics\u003c\/td\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003eHigher-validation workflow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA storage\u003c\/td\u003e\n\u003ctd\u003eDigital data\u003c\/td\u003e\n\u003ctd\u003eEarly-stage option value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235092668681,"sku":"twst-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/twst-ansoff-matrix.webp?v=1785734379","url":"https:\/\/dcfanalyst.com\/products\/twst-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}